Digital PCR dPCR

Digital PCR dPCR Market Outlook

The global Digital PCR (dPCR) market is projected to reach approximately USD 3.5 billion by 2035, growing at a CAGR of around 12.5% during the forecast period from 2025 to 2035. This robust growth can be attributed to the increasing demand for precise and sensitive quantification of nucleic acids, which is a vital process in clinical diagnostics and research. The rising prevalence of genetic disorders and cancer, alongside advancements in molecular diagnostics technologies, are key elements driving market expansion. Additionally, the growing focus on personalized medicine and the need for advanced diagnostic methods further propel the adoption of digital PCR technologies. With a surge in research activities and the integration of digital PCR in various applications, the market is poised for significant growth in the coming years.

Growth Factor of the Market

The Digital PCR market is experiencing a favorable growth trend largely due to the increasing prevalence of chronic diseases, including cancer, which necessitates early and accurate diagnosis. Moreover, advancements in digital PCR technology, such as improved sensitivity and specificity compared to traditional PCR methods, have propelled its utilization in various fields such as clinical diagnostics and environmental monitoring. The rising investment in research and development (R&D) to enhance digital PCR capabilities, combined with the growing emphasis on personalized medicine, is further driving the market's growth. Additionally, the expansion of biotechnology and pharmaceutical industries, along with increased funding for genomics research, creates a conducive environment for the digital PCR market. Furthermore, the ongoing global health crisis has highlighted the importance of rapid and accurate diagnostic testing, further boosting the demand for digital PCR solutions.

Key Highlights of the Market

• Projected market size of USD 3.5 billion by 2035 with a CAGR of 12.5%.
• Increased demand for accurate diagnostics in oncology driving market growth.
• Technological advancements enhancing sensitivity and specificity.
• Expansion of applications in environmental and forensic testing.
• Rising investments in R&D and genomic research driving innovation.

By Product Type

Droplet Digital PCR:

Droplet Digital PCR (ddPCR) is one of the most significant product types in the digital PCR market. It allows for the partitioning of a single sample into thousands of nanoliter-sized droplets, each serving as an individual reaction chamber. By quantifying the number of positive droplets, ddPCR provides absolute quantification of target DNA without the need for standard curves. This technology is particularly advantageous in applications such as mutation detection, copy number variation, and rare allele detection, where precision is essential. The increasing adoption of ddPCR in clinical diagnostics, especially for oncology applications, is contributing to its market growth.

Chip-based Digital PCR:

Chip-based Digital PCR utilizes microfluidic devices that enable the amplification and quantification of nucleic acids on a chip. This technology offers high-throughput capabilities, allowing multiple samples to be processed simultaneously, which significantly reduces turnaround time. The miniaturization and automation of the processes make it a preferred choice for researchers and laboratories focused on efficiency and scalability. As the demand for high-throughput screening in clinical and research applications increases, chip-based digital PCR is expected to gain traction in the market.

Bead-based Digital PCR:

Bead-based Digital PCR employs beads as reaction vessels for PCR amplification, providing a unique approach to digital PCR. Each bead is encapsulated with a sample, enabling a partitioned reaction that allows for high sensitivity in detecting low-abundance targets. This method is particularly valuable in applications such as single-cell analysis and rare variant detection. The growing emphasis on precision medicine and the need for sensitive diagnostic tools are factors driving the adoption of bead-based digital PCR in the market.

Reverse-transcription Digital PCR:

Reverse-transcription Digital PCR (RT-ddPCR) is an innovative technique that allows for the quantification of RNA, providing insights into gene expression levels. This method has become increasingly important in research areas like oncology and infectious diseases, where RNA analysis is critical. The ability to quantify mRNA levels with high accuracy and reproducibility makes RT-ddPCR an attractive option for researchers. As the understanding of RNA's role in diseases deepens, the demand for RT-ddPCR is projected to increase significantly.

Others:

The category of others includes various emerging digital PCR technologies that are continuously being developed. These methods may integrate novel approaches and platforms that enhance the sensitivity and efficiency of nucleic acid quantification. Innovations in instrumentation and the introduction of user-friendly interfaces are expected to foster the growth of these technologies within the digital PCR market. As researchers explore diverse applications, the 'Others' segment is anticipated to witness gradual growth as well.

By Application

Clinical Diagnostics:

In the application segment, clinical diagnostics holds the largest share of the digital PCR market. The precision and accuracy of digital PCR in quantifying DNA and RNA make it invaluable for detecting genetic disorders, infectious diseases, and cancers. The increasing demand for accurate diagnostic tools in personalized medicine and the growing need for early disease detection further bolster this segment. The ongoing advancements in digital PCR technologies are likely to enhance their application in clinical settings, thus driving significant growth in this segment.

Research:

The research application segment of the digital PCR market is fueled by the robust expansion of molecular biology and genomics research. Digital PCR provides researchers with precise quantification of nucleic acids, paving the way for breakthroughs in understanding genetic variations and their implications in diseases. As funding for genomics research continues to rise, the demand for advanced tools like digital PCR is expected to increase significantly, driving growth in this segment. Moreover, the rise of collaborative partnerships between academic institutions and biotechnology firms enhances the utilization of digital PCR in research settings.

Forensic Testing:

Forensic testing is emerging as a crucial application area for digital PCR due to its ability to analyze DNA samples with high precision and accuracy. Digital PCR is particularly beneficial in forensic scenarios where samples may be degraded or present in low quantities. The technology's ability to provide reliable results is essential for criminal investigations and paternity testing. As awareness of the advantages of digital PCR in forensic science grows, its adoption is expected to expand, driving growth in this application segment.

Environmental Testing:

Environmental testing is another growing application for digital PCR, focusing on detecting and quantifying nucleic acids in environmental samples such as water, soil, and air. This application is crucial for monitoring pathogens, assessing biodiversity, and analyzing pollution levels. The increasing concern over environmental health and safety, coupled with stringent regulatory requirements, is driving the demand for digital PCR solutions in this sector. As environmental testing becomes more critical, the adoption of digital PCR is expected to rise significantly.

Others:

The 'Others' segment encompasses a variety of applications where digital PCR is being explored, including agricultural testing, food safety analysis, and veterinary diagnostics. As the understanding of digital PCR technology expands, new applications continue to emerge, contributing to growth in this segment. The versatility of digital PCR enables its use in diverse fields, fostering innovation and expansion as researchers and industry players explore novel uses for this technology.

By End User

Hospitals and Diagnostic Centers:

Hospitals and diagnostic centers represent a substantial portion of the digital PCR market as they require reliable and accurate diagnostic tools for patient care. The ability to deliver precise results in a timely manner is particularly crucial in clinical settings, where early diagnosis can have significant implications for treatment outcomes. The growing adoption of digital PCR technologies in these facilities is driven by the increasing burden of chronic diseases, such as cancer, necessitating advanced diagnostic capabilities. Moreover, the integration of digital PCR into routine laboratory workflows enhances diagnostic efficiency, contributing to market growth in this segment.

Research Laboratories:

Research laboratories are another essential end-user segment in the digital PCR market, leveraging this technology for various research applications. The high sensitivity and specificity of digital PCR allow for precise quantification of nucleic acids, making it an indispensable tool in molecular biology, genetics, and oncology research. As funding for scientific research continues to increase, the demand for advanced molecular diagnostic tools like digital PCR is expected to expand, further driving market growth in this segment. Additionally, the collaborative efforts between academic and industrial researchers are expected to bring about innovative applications, boosting the adoption of digital PCR technologies.

Pharmaceutical and Biotechnology Companies:

The pharmaceutical and biotechnology sectors utilize digital PCR for drug development, clinical trials, and quality control. This technology facilitates precise measurement of biomarkers and genetic targets, enhancing the development of targeted therapies. The increasing focus on personalized medicine is driving pharmaceutical and biotechnology companies to adopt digital PCR for its ability to provide accurate insights into patient-specific responses to treatment. As these industries evolve, the demand for advanced molecular diagnostic tools will continue to grow, further propelling the digital PCR market.

Contract Research Organizations:

Contract Research Organizations (CROs) play a pivotal role in the pharmaceutical and biotechnology industries by providing outsourced research services, including digital PCR analysis. CROs are increasingly adopting digital PCR technologies to enhance their capabilities in performing clinical trials and research studies, providing clients with reliable data. The growing trend of outsourcing research activities drives the demand for digital PCR solutions among CROs, promoting market growth in this segment. As CROs continue to expand their service offerings, the integration of advanced diagnostic tools like digital PCR is expected to gain momentum.

Others:

The 'Others' category includes various end users such as governmental agencies, academic institutions, and non-profit organizations that are exploring digital PCR for various applications. These organizations may utilize digital PCR for research, environmental monitoring, or public health initiatives. As awareness of the benefits of digital PCR grows, these additional end users are anticipated to contribute to the overall market expansion. The versatility and adaptability of digital PCR technology make it suitable for a range of applications, fostering further growth in the market.

By Technology

Droplet Digital PCR (ddPCR):

Droplet Digital PCR (ddPCR) is the most widely adopted technology in the digital PCR segment due to its enhanced sensitivity and accuracy. By partitioning samples into thousands of droplets, ddPCR allows for precise quantification of nucleic acids without the need for standard curves. This technology is particularly advantageous for applications involving low-abundance targets, such as rare mutations or copy number variations. The ability to provide absolute quantification makes ddPCR a preferred choice for clinical diagnostics and research, driving continued growth in this sector.

BEAMing Digital PCR:

BEAMing Digital PCR is another innovative technology that combines emulsion PCR and bead-based enrichment to achieve high sensitivity in detecting rare mutations. This method is particularly useful in oncology applications where the detection of low-frequency mutations is crucial for personalized treatment. The increasing focus on precision medicine and targeted therapies is driving the demand for BEAMing Digital PCR in molecular diagnostics. As more researchers recognize the advantages of this technology, its adoption is expected to rise significantly.

Droplet-Linked Digital PCR:

Droplet-Linked Digital PCR is an emerging technology that combines the advantages of droplet-based systems with the ability to link multiple reactions together. This approach enhances the capability to detect multiple targets within a single assay, providing a more comprehensive analysis of genetic material. The potential for high-throughput applications and multiplexing makes droplet-linked digital PCR an attractive option for researchers and clinical laboratories alike. As the demand for efficient and effective diagnostic tools grows, this technology is expected to gain traction in the market.

Others:

The 'Others' category encompasses a variety of emerging digital PCR technologies that are currently under development or in early stages of adoption. These technologies may include novel platforms and methods that enhance the sensitivity and efficiency of nucleic acid quantification. As the digital PCR landscape continues to evolve, new innovations and applications are expected to emerge, contributing to the overall growth of the market. The ongoing research and investment in digital PCR technology will likely yield exciting advancements in the coming years.

By Droplet Digital PCR

Singleplex Droplet Digital PCR:

Singleplex Droplet Digital PCR allows for the quantification of a single target nucleic acid in a sample, providing high sensitivity and specificity. This technology is widely used in clinical diagnostics, particularly for detecting specific mutations in cancer genomics. The ability to measure low-abundance targets is a significant advantage in oncology applications, where accurate measurements are crucial for determining treatment paths. As the need for precise and reliable diagnostic tools continues to grow, singleplex ddPCR is expected to maintain a significant presence in the market.

Multiplex Droplet Digital PCR:

Multiplex Droplet Digital PCR enables the simultaneous quantification of multiple targets within a single reaction, enhancing the efficiency of analyses. This capability is particularly valuable in applications such as pathogen detection and genetic testing, where multiple markers need to be evaluated concurrently. The increasing need for comprehensive testing solutions in clinical diagnostics is driving the adoption of multiplex ddPCR technologies. As researchers and laboratories seek more efficient workflows, the demand for multiplex options is expected to rise significantly.

Integrated Droplet Digital PCR:

Integrated Droplet Digital PCR systems combine droplet generation, PCR amplification, and analysis into a single platform, simplifying workflows and reducing manual intervention. These systems enhance the usability of digital PCR technologies, making them more accessible for routine laboratory use. The convenience and efficiency offered by integrated systems are major factors driving their adoption in clinical and research settings. As laboratories continue to seek streamlined solutions, integrated droplet ddPCR technologies are likely to experience significant growth.

Others:

The 'Others' category encompasses various droplet digital PCR technologies that are in the development phase or have niche applications. These technologies may introduce novel approaches to nucleic acid quantification, expanding the overall capabilities of digital PCR. As research continues to advance in this field, the emergence of innovative solutions will contribute to the diversification of the digital PCR market, presenting new opportunities for growth.

By Region

The regional analysis of the Digital PCR market reveals that North America holds a significant share, accounting for approximately 40% of the global market. This dominance can be attributed to the presence of advanced healthcare infrastructure, robust research activities, and a growing focus on precision medicine. The United States, in particular, is witnessing a surge in demand for digital PCR technologies due to the increase in genetic testing and clinical diagnostics. The CAGR for the North American digital PCR market is projected to be around 13% during the forecast period, driven by technological advancements and increasing investments in biotechnology.

Europe follows closely, holding approximately 30% of the market share, with countries such as Germany, the United Kingdom, and France leading the way. The region's strong emphasis on research and development in molecular diagnostics, coupled with the rising prevalence of chronic diseases, is propelling growth in the digital PCR market. Additionally, supportive regulatory frameworks and funding initiatives for genomics research are fostering the adoption of digital PCR technologies. The Asia Pacific region is also emerging as a vital market, projected to grow at a CAGR of 15% during the forecast period, fueled by increasing healthcare expenditure and a growing focus on personalized medicine.

Opportunities

The Digital PCR market is poised for substantial growth, presenting numerous opportunities for stakeholders across various segments. One of the most significant opportunities lies in the expanding applications of digital PCR in personalized medicine. As the healthcare industry increasingly shifts toward tailored treatment approaches based on individual genetic profiles, the demand for precise and reliable diagnostic tools will continue to rise. Digital PCR's ability to provide accurate quantification of nucleic acids plays a critical role in identifying suitable therapies for patients, particularly in oncology and rare genetic disorders. This trend is expected to create new avenues for innovation and investment in digital PCR technologies.

Another promising opportunity is the growing emphasis on environmental monitoring and pathogen detection. The need for rapid and accurate testing methods has gained prominence, particularly in the wake of global health crises. Digital PCR offers the sensitivity required to detect low-level pathogens in various environmental samples, making it an invaluable tool for public health and safety. As regulatory bodies impose stricter guidelines for environmental testing, the adoption of digital PCR technologies is anticipated to increase significantly. This expanding application area represents a lucrative opportunity for market players to develop and market digital PCR solutions tailored to environmental and public health needs.

Threats

Despite the promising growth outlook for the Digital PCR market, there are certain threats that could impede its progress. One of the primary concerns is the high cost associated with digital PCR technologies compared to traditional PCR methods. The complexity of the technology and the need for specialized equipment can deter smaller laboratories and institutions from adopting digital PCR solutions. Furthermore, the initial investment required for implementing digital PCR systems may pose a barrier for some organizations, particularly in developing regions. If the cost of these technologies does not decrease over time, it may hinder widespread adoption and limit market growth.

Additionally, the regulatory landscape surrounding molecular diagnostics is constantly evolving, which can pose challenges for market players. Compliance with stringent regulations and obtaining necessary approvals can be time-consuming and costly for companies developing digital PCR products. Variability in regulatory requirements across different regions may further complicate market entry and expansion strategies for manufacturers. Companies must remain vigilant and adapt to changing regulations to mitigate these threats and ensure successful market penetration.

Competitor Outlook

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• Becton, Dickinson and Company.
• Agilent Technologies, Inc.
• Stilla Technologies.
• Jena Bioscience GmbH.
• RainDance Technologies, Inc.
• Fluidigm Corporation.
• Merck KGaA
• Genomatix Software GmbH.
• PerkinElmer, Inc.
• Michaelson Diagnostics Ltd.
• QIAGEN GmbH.
• Roche Diagnostics.

The competitive landscape of the Digital PCR market is characterized by several key players who are actively investing in research and development to enhance their technology offerings. Companies like Thermo Fisher Scientific and Bio-Rad Laboratories are leading the way, leveraging their extensive expertise in molecular diagnostics to develop innovative digital PCR platforms. Their commitment to providing high-quality products and services positions them favorably in the market, allowing them to capitalize on the growing demand for digital PCR solutions. Additionally, these companies often engage in strategic partnerships and collaborations to expand their market reach and enhance their product portfolios.

Qiagen N.V. and Becton, Dickinson and Company are also notable players in the digital PCR market, focusing on the development of advanced technologies that cater to both clinical and research applications. Qiagen, for example, has made significant strides in integrating digital PCR into its existing product lines, ensuring compatibility with various laboratory workflows. Becton, Dickinson and Company is continuously working to enhance its digital PCR capabilities, targeting the growing demand for precise and efficient diagnostic solutions. These companies aim to maintain their competitive edge by investing in innovative products and expanding their distribution networks.

Emerging companies such as Stilla Technologies and RainDance Technologies are making their mark in the digital PCR landscape by introducing novel technologies that address specific market needs. Stilla Technologies, for instance, has developed the Naica System, which utilizes a unique digital PCR approach that enables multiplexing capabilities for more comprehensive analyses. RainDance Technologies focuses on providing highly sensitive digital PCR solutions that cater to both clinical and research applications. As these emerging players continue to innovate and bring new technologies to market, the competitive dynamics of the digital PCR industry are expected to evolve, leading to increased opportunities for growth and collaboration.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Qiagen N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 QIAGEN GmbH.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 PerkinElmer, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Diagnostics.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Stilla Technologies.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Fluidigm Corporation.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Jena Bioscience GmbH.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Genomatix Software GmbH.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Agilent Technologies, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bio-Rad Laboratories, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Michaelson Diagnostics Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 RainDance Technologies, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Becton, Dickinson and Company.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Digital PCR dPCR Market, By End User
    • 6.1.1 Hospitals and Diagnostic Centers
    • 6.1.2 Research Laboratories
    • 6.1.3 Pharmaceutical and Biotechnology Companies
    • 6.1.4 Contract Research Organizations
    • 6.1.5 Others
  • 6.2 Digital PCR dPCR Market, By Technology
    • 6.2.1 Droplet Digital PCR (ddPCR)
    • 6.2.2 BEAMing Digital PCR
    • 6.2.3 Droplet-Linked Digital PCR
    • 6.2.4 Others
  • 6.3 Digital PCR dPCR Market, By Application
    • 6.3.1 Clinical Diagnostics
    • 6.3.2 Research
    • 6.3.3 Forensic Testing
    • 6.3.4 Environmental Testing
    • 6.3.5 Others
  • 6.4 Digital PCR dPCR Market, By Product Type
    • 6.4.1 Droplet Digital PCR
    • 6.4.2 Chip-based Digital PCR
    • 6.4.3 Bead-based Digital PCR
    • 6.4.4 Reverse-transcription Digital PCR
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Digital PCR dPCR Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Digital PCR dPCR market is categorized based on

By Product Type

• Droplet Digital PCR
• Chip-based Digital PCR
• Bead-based Digital PCR
• Reverse-transcription Digital PCR
• Others

By Application

• Clinical Diagnostics
• Research
• Forensic Testing
• Environmental Testing
• Others

By End User

• Hospitals and Diagnostic Centers
• Research Laboratories
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Others

By Technology

• Droplet Digital PCR (ddPCR)
• BEAMing Digital PCR
• Droplet-Linked Digital PCR
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• Becton, Dickinson and Company.
• Agilent Technologies, Inc.
• Stilla Technologies.
• Jena Bioscience GmbH.
• RainDance Technologies, Inc.
• Fluidigm Corporation.
• Merck KGaA
• Genomatix Software GmbH.
• PerkinElmer, Inc.
• Michaelson Diagnostics Ltd.
• QIAGEN GmbH.
• Roche Diagnostics.